Magnetomotoric Ultrasound (MMUS) in Rectal Cancer (MAMORECT)
Primary Purpose
Rectal Cancer
Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Magnetomotoric ultrasound
Sponsored by
About this trial
This is an interventional diagnostic trial for Rectal Cancer
Eligibility Criteria
Inclusion Criteria:
- Rectal cancer
- Scheduled for total mesorectal surgery
- Informed consent
Exclusion Criteria:
- Not able to give informed consent
- Synchronus colorectal cancer
Sites / Locations
- Skane University Hospital, Malmö, section of SurgeryRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Magnetomotoric ultrasound
Arm Description
Magnetomotoric ultrasound in addition to MRI.
Outcomes
Primary Outcome Measures
Accuracy of mesorectal lymph node diagnosis with MMUS, compared with final histopathology
Evaluation of the accuracy of MMUS in detecting lymph node metastases in rectal cancer. The results of the MMUS (malignant or benign lymph nodes) will be compared with final histopathology. The accuracy will be expressed in sensitivity (%), specificity (%) and overall accuracy (% correctly staged lymph nodes with MMUS)
Accuracy of mesorectal lymph node diagnosis with MMUS, compared with preoperative MRI
Evaluation of the accuracy of MMUS in detecting lymph node metastases in rectal cancer in comparison to standard staging (MRI). The results of the MMUS (malignant nodes or benign nodes) will be compared with the results of preoperative MRI (malignant or benign lymph nodes) and the final histopathology. The accuracy will be expressed in sensitivity (%), specificity (%) and overall accuracy (% correctly staged lymph nodes) with MMUS and MRI.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05052086
Brief Title
Magnetomotoric Ultrasound (MMUS) in Rectal Cancer
Acronym
MAMORECT
Official Title
Magnetomotoric Ultrasound (MMUS) in the Staging of Rectal Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2022 (Actual)
Primary Completion Date
December 20, 2023 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Skane
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Magnetomotoric ultrasound, combines conventional ultrasound with a time-varying magnetic field. The aim is to improve diagnosis of mesolectal lymph nodes.
Detailed Description
Magnetomotoric ultrasound, combines conventional ultrasound with a time-varying magnetic field. Nanoparticles are injected close to the rectal cancer and migrate to adjacent lymph nodes.The time-varying magnetic field will influence the nano particles in the lymph node enhancing diagnosis of affected lymph nodes. The aim is to improve diagnosis of mesolectal lymph nodes and compare the results of magnetomotoric ultrasound with MRI and final histopathology.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rectal Cancer
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Included patients will undergo magnetomotoric ultrasound in addition to conventional MRI. The results of MRI examination and magnetomotoric ultrasound will be compared with final histopathology.
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Magnetomotoric ultrasound
Arm Type
Experimental
Arm Description
Magnetomotoric ultrasound in addition to MRI.
Intervention Type
Diagnostic Test
Intervention Name(s)
Magnetomotoric ultrasound
Intervention Description
Nanoparticles will be injected close to the tumor. Magnetomotoric ultrasound will be performed just before scheduled standard operation, when the patient is anesthetized.
Primary Outcome Measure Information:
Title
Accuracy of mesorectal lymph node diagnosis with MMUS, compared with final histopathology
Description
Evaluation of the accuracy of MMUS in detecting lymph node metastases in rectal cancer. The results of the MMUS (malignant or benign lymph nodes) will be compared with final histopathology. The accuracy will be expressed in sensitivity (%), specificity (%) and overall accuracy (% correctly staged lymph nodes with MMUS)
Time Frame
Approximately 1 hour after MMUS
Title
Accuracy of mesorectal lymph node diagnosis with MMUS, compared with preoperative MRI
Description
Evaluation of the accuracy of MMUS in detecting lymph node metastases in rectal cancer in comparison to standard staging (MRI). The results of the MMUS (malignant nodes or benign nodes) will be compared with the results of preoperative MRI (malignant or benign lymph nodes) and the final histopathology. The accuracy will be expressed in sensitivity (%), specificity (%) and overall accuracy (% correctly staged lymph nodes) with MMUS and MRI.
Time Frame
Approximately 1 hour after MMUS
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Rectal cancer
Scheduled for total mesorectal surgery
Informed consent
Exclusion Criteria:
Not able to give informed consent
Synchronus colorectal cancer
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Carl-Fredrik Rönnow, MD, PhD
Phone
+4640-331635
Email
carl-fredrik.ronnow@med.lu.se
First Name & Middle Initial & Last Name or Official Title & Degree
Henrik Thorlacius, Professor
Phone
+46 40-331000
Email
henrik.thorlacius@med.lu.se
Facility Information:
Facility Name
Skane University Hospital, Malmö, section of Surgery
City
Malmö
State/Province
Skåne
ZIP/Postal Code
20501
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Carl-Fredrik Rönnow, MD, PhD
Phone
+46 40-331635
Email
carl-fredrik.ronnow@med.lu.se
First Name & Middle Initial & Last Name & Degree
Henrik Thorlacius, Professor
Phone
+46 40-331000
Email
henrik.thorlacius@med.lu.se
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Magnetomotoric Ultrasound (MMUS) in Rectal Cancer
We'll reach out to this number within 24 hrs